Insys Therapeutics intends to raise up to $82.8 million in an initial public offering of 4 million shares priced at $16 to $18 each plus the sale of additional shares to meet overallotments; the IPO would move the Phoenix, Arizona-based company to the Nasdaq from the Over-the-Counter market to generate much needed cash from a larger pool of investors.
Insys, which focuses on cancer supportive care and other products, closed at $11.99 per share on 19 April on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?